Literature DB >> 22128345

Dysfunction of extrasynaptic GABAergic transmission in phospholipase C-related, but catalytically inactive protein 1 knockout mice is associated with an epilepsy phenotype.

Gang Zhu1, Shukuko Yoshida, Keisuke Migita, Junko Yamada, Fumiaki Mori, Masahiko Tomiyama, Koichi Wakabayashi, Takashi Kanematsu, Masato Hirata, Sunao Kaneko, Shinya Ueno, Motohiro Okada.   

Abstract

Phospholipase C-related, but catalytically inactive protein (PRIP) was first identified as a novel inositol 1,4,5-triphosphate binding protein. The PRIP-1 subtype is expressed predominantly in the central nervous system and binds directly to the GABA type A receptor (GABA(A)-R) β-subunit and several other proteins involved in the trafficking of GABA(A)-Rs to the plasma membrane. We found that the PRIP-1 knockout mouse showed an epileptic phenotype, confirmed by electroencephalogram. These ictal seizures were completely suppressed by diazepam (DZP), but the interictal discharges could not be abolished. We studied the electrophysiological properties of GABAergic transmission in hippocampal CA1 pyramidal neurons, using a slice patch-clamp technique. There was no difference in the effect of up to 1 μM DZP on the amplitude and frequency of miniature inhibitory postsynaptic currents between PRIP-1 knockout neurons versus wild-type neurons. In contrast, the amplitude of the tonic GABA current in PRIP-1 knockout neurons was markedly reduced compared with that in wild-type neurons. Consequently, the effect of DZP on PRIP-1 knockout mice was reduced. Dysfunction of extrasynaptic GABAergic transmission probably is involved in the epileptic phenotype of PRIP-1 knockout mice.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22128345     DOI: 10.1124/jpet.111.182386

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  7 in total

1.  Phospholipase C-related inactive protein type-1 deficiency affects anesthetic electroencephalogram activity induced by propofol and etomidate in mice.

Authors:  Tomonori Furukawa; Yoshikazu Nikaido; Shuji Shimoyama; Yoshiki Ogata; Tetsuya Kushikata; Kazuyoshi Hirota; Takashi Kanematsu; Masato Hirata; Shinya Ueno
Journal:  J Anesth       Date:  2019-07-22       Impact factor: 2.078

2.  Clptm1 Limits Forward Trafficking of GABAA Receptors to Scale Inhibitory Synaptic Strength.

Authors:  Yuan Ge; Yunhee Kang; Robert M Cassidy; Kyung-Mee Moon; Renate Lewis; Rachel O L Wong; Leonard J Foster; Ann Marie Craig
Journal:  Neuron       Date:  2018-01-25       Impact factor: 17.173

Review 3.  Phosphoinositides: tiny lipids with giant impact on cell regulation.

Authors:  Tamas Balla
Journal:  Physiol Rev       Date:  2013-07       Impact factor: 37.312

4.  Early postnatal switch in GABAA receptor α-subunits in the reticular thalamic nucleus.

Authors:  Susanne Pangratz-Fuehrer; Werner Sieghart; Uwe Rudolph; Isabel Parada; John R Huguenard
Journal:  J Neurophysiol       Date:  2015-12-02       Impact factor: 2.714

5.  GABA Signaling Pathway-associated Gene PLCL1 Rare Variants May be Associated with Autism Spectrum Disorders.

Authors:  Fengyun Zheng; Guoyuan Liu; Ting Dang; Qiaowen Chen; Yu An; Meng Wu; Xiangxuan Kong; Zilong Qiu; Bai-Lin Wu
Journal:  Neurosci Bull       Date:  2021-06-05       Impact factor: 5.271

6.  Phenome-wide association study (PheWAS) in EMR-linked pediatric cohorts, genetically links PLCL1 to speech language development and IL5-IL13 to Eosinophilic Esophagitis.

Authors:  Bahram Namjou; Keith Marsolo; Robert J Caroll; Joshua C Denny; Marylyn D Ritchie; Shefali S Verma; Todd Lingren; Aleksey Porollo; Beth L Cobb; Cassandra Perry; Leah C Kottyan; Marc E Rothenberg; Susan D Thompson; Ingrid A Holm; Isaac S Kohane; John B Harley
Journal:  Front Genet       Date:  2014-11-18       Impact factor: 4.599

Review 7.  γ2 GABAAR Trafficking and the Consequences of Human Genetic Variation.

Authors:  Joshua M Lorenz-Guertin; Matthew J Bambino; Tija C Jacob
Journal:  Front Cell Neurosci       Date:  2018-08-23       Impact factor: 5.505

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.